<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768039</url>
  </required_header>
  <id_info>
    <org_study_id>MS-1191</org_study_id>
    <nct_id>NCT01768039</nct_id>
  </id_info>
  <brief_title>Vitamine D in Multiple Sclerosis</brief_title>
  <acronym>MSVit</acronym>
  <official_title>Randomised Double Blind Placebo-controlled Trial of Vitamine D Supplement in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mazandaran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mazandaran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two hundred and forty patients with multiple sclerosis who met the study criteria will be&#xD;
      enrolled in this randomized double blind placebo-controlled clinical trial.&#xD;
&#xD;
      They will randomly assigned to placebo or vitamin D treatment group. The total time of study&#xD;
      is 52 weeks and the vitamin D group will be treated by weekly 50000 International unit(IU)&#xD;
      vitamin D, while the other group will receive weekly placebo. The annual relapse rate and&#xD;
      EDSS will be compared at baseline, month 6 and 12.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expanded disability state scale score (EDSS)</measure>
    <time_frame>Changes in EDSS from baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual relapse rate(ARR)</measure>
    <time_frame>Changes in ARR from baseline to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with weekly 50000IU vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>Vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI:18-30kg/m2&#xD;
&#xD;
          -  caucasian race&#xD;
&#xD;
          -  Relapsing remitting multiple sclerosis&#xD;
&#xD;
          -  treatment with interferon beta&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent vitamin D supplement therapy&#xD;
&#xD;
          -  Restricted fat diet&#xD;
&#xD;
          -  nephrolithiasis in recent 5 years&#xD;
&#xD;
          -  Past history of hyperparathyroidism, sarcoidosis, cancer&#xD;
&#xD;
          -  Past history of hepatic disease&#xD;
&#xD;
          -  Past history of gastrointestinal disease&#xD;
&#xD;
          -  Past history of mycobacterial infection&#xD;
&#xD;
          -  Past history of hypercalcemia and hypercalciuria&#xD;
&#xD;
          -  serum creatinine&gt;1.5&#xD;
&#xD;
          -  Smoking, drug abuse and corticosteroid therapy in recent year&#xD;
&#xD;
          -  treatment with thiazides or other drugs that inhibit vitamin D absorption&#xD;
&#xD;
          -  Disease attack in recent 2 months&#xD;
&#xD;
          -  Serum Ca&gt;2.6mm0l/L&#xD;
&#xD;
          -  Serum 25(OH)D&gt;85mmol/L&#xD;
&#xD;
          -  hypersensitivity to cholecalciferol&#xD;
&#xD;
          -  Past history of heart disease&#xD;
&#xD;
          -  Major depression&#xD;
&#xD;
          -  Uncontrolled hypertension (BP&gt;180/110)&#xD;
&#xD;
          -  Immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mahmoud Abedini, MD</last_name>
    <phone>01513243158</phone>
    <email>mahmoudabedini@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mazandaran University of medical sciences</name>
      <address>
        <city>Sari</city>
        <state>Mazandaran</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mahmoud Abedini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>January 11, 2013</last_update_submitted>
  <last_update_submitted_qc>January 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mazandaran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mahmoud Abedini</investigator_full_name>
    <investigator_title>associate professor of neurology</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>EDSS</keyword>
  <keyword>ARR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

